This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
Invitrogen
other brands :
NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience
product type :
protein
product name :
Human FAM193B (aa 482-574) Control Fragment Recombinant Protein
catalog :
RP-94989
quantity :
100 uL
price :
US 259.00
product information
Product Type :
Protein
Product Name :
Human FAM193B (aa 482-574) Control Fragment Recombinant Protein
Catalog # :
RP-94989
Quantity :
100 uL
Price :
US 259.00
Clonality :
Recombinant
Purity :
purified
Reactivity :
Human
Applications :
Blocking Assay: Assay-dependent, Control: Assay-dependent
Species :
Human
Storage :
-20 C, Avoid Freeze/Thaw Cycles
Description :
FAM193B, also known as IRIZIO, was initially identified as a protein that is upregulated in alveolar rhabdomyosarcoma (ARMS), a type of fast-growing tumor characterized by chromosomal translocations fusing the PAX3 or PAX7 gene with that of FOXO1. It has been suggested that, in addition to the PAX3-FOXO1 gene fusion, disruption of the Rb and p53 pathways is required for full ARMS tumorigenesis. In PAX3-FOXO1-expressing primary mouse fibroblasts that possessed a defective p53 pathway, FAM193B expression enabled the tumorigenic transformation, suggesting that FAM193B may contribute to rhabdomyosarcomagenesis in humans.
Format :
Liquid
Applications w/Dilutions :
Blocking Assay: Assay-dependent, Control: Assay-dependent
Aliases :
FAM193B; family with sequence similarity 193 member B; IRIZIO; KIAA1931; Protein FAM193B
company information
Invitrogen
Thermo Fisher Scientific
81 Wyman Street
Waltham, MA USA 02451
https://www.thermofisher.com81 Wyman Street
Waltham, MA USA 02451
800-678-5599
headquarters: USA
questions and comments